Literature DB >> 1455909

Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide.

C C Peeters1, A M Tenbergen-Meekes, J T Poolman, B J Zegers, G T Rijkers.   

Abstract

In this study we report that the priming capacity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate to booster immunizations with the native capsular polysaccharide is dose dependent. Furthermore, it is shown by admixture experiments that simultaneous administration of high doses of free saccharide (0.5-25 micrograms) of different chain lengths (varying from M(r) 1.6-120 kDa) decreases the anti-polysaccharide antibody response. Presence of low doses of saccharide (up to 10%), which are usually present in conjugates prepared by the carbodiimide coupling procedure, did not influence the anti-polysaccharide antibody response in adult and neonatal mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455909     DOI: 10.1016/0264-410x(92)90046-m

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

2.  Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

Authors:  S T Test; J Mitsuyoshi; C C Connolly; A H Lucas
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Experimental design to optimize an Haemophilus influenzae type b conjugate vaccine made with hydrazide-derivatized tetanus toxoid.

Authors:  Craig Laferriere; Neil Ravenscroft; Seanette Wilson; Jill Combrink; Lizelle Gordon; Jean Petre
Journal:  Glycoconj J       Date:  2011-08-19       Impact factor: 2.916

4.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.

Authors:  Simona Rondini; Francesca Micoli; Luisa Lanzilao; Christine Hale; Allan J Saul; Laura B Martin
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

Review 6.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

7.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

8.  Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.

Authors:  Cyrille Grandjean; Alain Boutonnier; Bruno Dassy; Jean-Michel Fournier; Laurence A Mulard
Journal:  Glycoconj J       Date:  2008-07-23       Impact factor: 2.916

9.  On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.

Authors:  Maruthi Prasanna; Malgorzata Podsiadla-Bialoskorska; Damian Mielecki; Nicolas Ruffier; Amina Fateh; Annie Lambert; Mathieu Fanuel; Emilie Camberlein; Ewa Szolajska; Cyrille Grandjean
Journal:  Glycoconj J       Date:  2021-04-14       Impact factor: 2.916

Review 10.  Hib Vaccines: Past, Present, and Future Perspectives.

Authors:  Adi Essam Zarei; Hussein A Almehdar; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-01-20       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.